Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
NCT07239973Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing BGM0504 tablets with Placebo tablets (2 arms). Primary endpoint: Number of treatment adverse events at 8 weeks. Started Oct 2025; status: completed.
02
Drugs
BGM0504
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07239973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239973.